Royalty Pharma plc (rprx)
RPRX Earnings
Public earnings and growth snapshot for Royalty Pharma plc. Full earnings calendars, surprises, and multi-year history are available in Vest Terminal.
| Earnings growth (YoY) | -46.3% |
| Revenue growth (YoY) | 16.5% |
| Trailing P/E | 30.99 |
| Forward P/E | 10.05 |
| Last price | $57.65 |
| Market cap | $33.31B |
Start Free — open RPRX in Vest Terminal
Access live data, filings, ownership, and analysis for Royalty Pharma plc.
Royalty Pharma plc FAQ
What does Royalty Pharma plc (RPRX) do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that ad…
What is RPRX's P/E ratio?
Royalty Pharma plc has a trailing P/E of 30.99× based on publicly available market data.
Does RPRX pay a dividend?
Indicated dividend yield: 1.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is RPRX in?
Royalty Pharma plc is classified in Healthcare (Biotechnology) on NMS.
What is RPRX's market capitalization?
Approximate market cap: $33.31B.
What are the main risks for RPRX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of RPRX?
Potential positives include revenue growth of 16.5% year-over-year, gross margin of 95.8% supports competitive unit economics.
Where can I get analyst estimates for RPRX?
Public analyst price targets and consensus for Royalty Pharma plc are on the free /stocks/rprx/estimates page. Deeper estimate history and models are available in Vest Terminal.